773 related articles for article (PubMed ID: 16682454)
1. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
[TBL] [Abstract][Full Text] [Related]
2. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
[TBL] [Abstract][Full Text] [Related]
3. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
4. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators.
Fujimura T; Sakuma H; Konishi S; Oe T; Hosogai N; Kimura C; Aramori I; Mutoh S
J Pharmacol Sci; 2005 Dec; 99(4):342-52. PubMed ID: 16314690
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
Minoura H; Takeshita S; Ita M; Hirosumi J; Mabuchi M; Kawamura I; Nakajima S; Nakayama O; Kayakiri H; Oku T; Ohkubo-Suzuki A; Fukagawa M; Kojo H; Hanioka K; Yamasaki N; Imoto T; Kobayashi Y; Mutoh S
Eur J Pharmacol; 2004 Jun; 494(2-3):273-81. PubMed ID: 15212984
[TBL] [Abstract][Full Text] [Related]
6. Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands.
Rival Y; Stennevin A; Puech L; Rouquette A; Cathala C; Lestienne F; Dupont-Passelaigue E; Patoiseau JF; Wurch T; Junquéro D
J Pharmacol Exp Ther; 2004 Nov; 311(2):467-75. PubMed ID: 15273253
[TBL] [Abstract][Full Text] [Related]
7. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat.
Minoura H; Takeshita S; Yamamoto T; Mabuchi M; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Ita M; Mutoh S
Eur J Pharmacol; 2005 Sep; 519(1-2):182-90. PubMed ID: 16039648
[TBL] [Abstract][Full Text] [Related]
8. Magnolol enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells.
Choi SS; Cha BY; Lee YS; Yonezawa T; Teruya T; Nagai K; Woo JT
Life Sci; 2009 Jun; 84(25-26):908-14. PubMed ID: 19376135
[TBL] [Abstract][Full Text] [Related]
9. KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects.
Kim KR; Lee JH; Kim SJ; Rhee SD; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
Biochem Pharmacol; 2006 Aug; 72(4):446-54. PubMed ID: 16797489
[TBL] [Abstract][Full Text] [Related]
10. A high-capacity assay for PPARgamma ligand regulation of endogenous aP2 expression in 3T3-L1 cells.
Thompson GM; Trainor D; Biswas C; LaCerte C; Berger JP; Kelly LJ
Anal Biochem; 2004 Jul; 330(1):21-8. PubMed ID: 15183757
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 modulates adipocyte differentiation.
Liang X; Kanjanabuch T; Mao SL; Hao CM; Tang YW; Declerck PJ; Hasty AH; Wasserman DH; Fogo AB; Ma LJ
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E103-E113. PubMed ID: 16144810
[TBL] [Abstract][Full Text] [Related]
12. Bixin regulates mRNA expression involved in adipogenesis and enhances insulin sensitivity in 3T3-L1 adipocytes through PPARgamma activation.
Takahashi N; Goto T; Taimatsu A; Egawa K; Katoh S; Kusudo T; Sakamoto T; Ohyane C; Lee JY; Kim YI; Uemura T; Hirai S; Kawada T
Biochem Biophys Res Commun; 2009 Dec; 390(4):1372-6. PubMed ID: 19891958
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
14. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
[TBL] [Abstract][Full Text] [Related]
15. The DLK gene is a transcriptional target of PPARγ.
Couture JP; Blouin R
Biochem J; 2011 Aug; 438(1):93-101. PubMed ID: 21585338
[TBL] [Abstract][Full Text] [Related]
16. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
[TBL] [Abstract][Full Text] [Related]
17. The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPARgamma agonist restores normal cell signaling and differentiation.
Sentinelli F; Filippi E; Cavallo MG; Romeo S; Fanelli M; Baroni MG
J Endocrinol; 2006 Feb; 188(2):271-85. PubMed ID: 16461553
[TBL] [Abstract][Full Text] [Related]
18. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.
Moyers JS; Shiyanova TL; Mehrbod F; Dunbar JD; Noblitt TW; Otto KA; Reifel-Miller A; Kharitonenkov A
J Cell Physiol; 2007 Jan; 210(1):1-6. PubMed ID: 17063460
[TBL] [Abstract][Full Text] [Related]
19. Astaxanthin functions differently as a selective peroxisome proliferator-activated receptor γ modulator in adipocytes and macrophages.
Inoue M; Tanabe H; Matsumoto A; Takagi M; Umegaki K; Amagaya S; Takahashi J
Biochem Pharmacol; 2012 Sep; 84(5):692-700. PubMed ID: 22732454
[TBL] [Abstract][Full Text] [Related]
20. Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma.
Fujimura T; Sakuma H; Ohkubo-Suzuki A; Aramori I; Mutoh S
Biol Pharm Bull; 2006 Mar; 29(3):423-9. PubMed ID: 16508139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
